WAM
NKTR icon

Wolverine Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Wolverine Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-13
Closed -$1K – 2085
2014
Q4 		$1K Hold
13
– – ﹤0.01% 2049
2014
Q3 		$7K Buy
+13
New +$2.49K ﹤0.01% 2071
2013
Q3 		– Sell
-34
Closed -$9K – 2812
2013
Q2 		$9K Buy
+34
New +$5.21K ﹤0.01% 2240

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Wolverine Asset Management's NKTR Position: Q4 2020 in Review

Wolverine Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 1,706 shares — an estimated $424K sold.

Wolverine Asset Management first reported a position in NKTR in Q2 2013 and held it in 5 quarters. The position peaked at $424K in Q3 2020. 245 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • Wolverine Asset Management reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wolverine Asset Management sold 1,706 Nektar Therapeutics shares in Q4 2020, an estimated $424K.
  • Wolverine Asset Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 5 quarters.
  • Wolverine Asset Management's Nektar Therapeutics position peaked at $424K in Q3 2020.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Wolverine Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.